Telesis Bio

Telesis Bio Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Telesis Bio (TBIO) as of Oct 20, 2026 is 72.64 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 79.87 % — a change of -9.05% (lower).

Cash Conversion

72.64 %

YoY

-9.05%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Telesis Bio is 2023 72.64 % . Cash Conversion Rate (OCF/Net Income) of Telesis Bio was 2022 79.87 % . It decreases by -9.05% lower compared to the previous year.

The Telesis Bio Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2016
88.84 USD
Jan 1, 2017
76.44 USD
Jan 1, 2018
22.72 USD
Jan 1, 2019
76.97 USD
Jan 1, 2020
85.40 USD
Jan 1, 2021
94.20 USD
Jan 1, 2022
79.87 USD
Jan 1, 2023
72.64 USD
The Telesis Bio Cash Conversion history
YEARCash ConversionYoY
72.64 %-9.05%
79.87 %-15.21%
94.20 %+10.30%
85.40 %+10.96%
76.97 %+238.70%
22.72 %-70.27%
76.44 %-13.96%
88.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telesis Bio Stock analysis

What does Telesis Bio do? Telesis Bio Inc, trading under the ticker TBIO with ISIN US1920032000, is a U.S.-based company headquartered in San Diego. It operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company has 212 employees and completed its initial public offering on June 18, 2021. Telesis Bio Inc's website is https://codexdna.com/. The company focuses on research and development of genomic tools for biomedical and industrial applications. Its synthetic biology solutions aim to address challenges in the multi-step process of constructing DNA and mRNA, overcoming limitations that hinder scalable production. The BioXp system, an end-to-end automated workstation, is a key product offering. The company provides BioXp systems, including the BioXp 3250 model, along with BioXp kits for generating synthetic DNA and mRNA, and benchtop reagents designed to support automated synthetic biology workflows. Additional products include eight BioXp kits, three benchtop reagent kits, and various synthetic biology solutions such as 14 SARS-CoV-2 full-length genomes and RNA controls. The company has deployed approximately 200 BioXp systems globally. Telesis Bio Inc is engaged in developing tools that enhance the efficiency and scalability of genomic research and applications. Telesis Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telesis Bio stock

Cash Conversion Rate (OCF/Net Income) of Telesis Bio is 72.64 % in 2023.

Cash Conversion Rate (OCF/Net Income) of Telesis Bio changed from 79.87 % to 72.64 %, representing a -9.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Telesis Bio since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Telesis Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Telesis Bio

All Key Metrics — Telesis Bio